This includes individuals with: Diagnosed MASLD or MASH, where GLP-1 therapy may offer therapeutic benefits but requires monitoring Chronic viral hepatitis (hepatitis B or C), particularly if transaminases are elevated Autoimmune hepatitis or other inflammatory liver conditions Cirrhosis or advanced fibrosis, where specialist consultation may be appropriate despite generally not requiring dose adjustment History of drug-induced liver injury from other agents For these patients, baseline comprehensive liver assessmentincluding liver enzymes, synthetic function tests (albumin, INR), and potentially imaging or non-invasive fibrosis markers (such as FIB-4 or ELF)helps establish a reference point for monitoring treatment effects
What they cost in 2026 List price and what anyone actually pays are two different numbers, and the gap has become enormous
This approach is still emerging but represents an interesting frontier for thyroid patients who want immune-modulating effects without aggressive weight loss
FDA vowed to detain shipments from unverified sources as part of a push to protect U.S
Growth Hormone Induces Colon DNA Damage Independent of IGF-1 [PMID: 31002310] Laboratory literature summary: Growth Hormone Induces Colon DNA Damage Independent of IGF-1